参松养心胶囊抗心律失常的疗效和安全性系统评价

目的系统评价参松养心胶囊抗心律失常的有效性和安全性。方法计算机检索CBM、CNKI、VIP、万方、PubMed、Cochrane图书馆临床对照试验资料库等数据库,同时筛查纳入文献的参考文献,按纳入与排除标准纳入参松养心胶囊防治心律失常的随机对照试验(RCTs)。由两名评价员独立评价文献质量、提取资料并交叉核对,而后采用RevMan 5.0软件进行Meta分析。结果共纳入13个研究,包括1896例患者,其研究质量均为C级。Meta分析结果显示:与对照组比较,①在疗效方面,参松养心胶囊优于美西律OR=2.96,95%CI(1.79,4.87)]、心律平OR=2.41,95%CI(1.60,3.62)],但与胺碘酮无显著差异OR=1.25,95%CI(0.88,1.71)]。②在安全性方面,致心律失常发生率参松养心胶囊明显低于心律平OR=0.06,95%CI(0.01,0.35)]和胺碘酮OR=0.05,95%CI(0.02,0.17)],胃肠道不良反应发生率参松养心胶囊与对照组相比差异无统计学意义。结论现有证据表明,参松养心胶囊抗心律失常疗效与目前常用的西药相当,而致心律失常率发生较低,胃肠道不良反应发生率与西药无明显差异。受纳入文献质量限制,其疗效评价需更多高质量的随机双盲对照试验加以证实。

Efficacy and Safety of Shen Song Yang Xin Capsule for Cardiac Arrhythmia: A Systematic Review

Objective To evaluate the efficacy and safety of Shen Song Yang Xin Capsule for cardiac arrhythmia.Methods Randomized controlled trials(RCTs) were searched from the following electronic databases: WanFang,CNKI,CBM,VIP,PubMed,and The Cochrane Library.Quality assessment and data extraction were conducted by two reviewers independently.Disagreement was resolved through discussion.All data were analyzed by using RevMan 5.0 software.Results Thirteen studies involving 1896 participants were included.The results o...